Irish CRO Venn Life Sciences has agreed to trade nearly $1 million of stock for Germany's CRM Clinical Trials, a move that will stretch its reach into one of Europe's largest research markets. Venn expects CRM to add about $2 million in revenue for 2014, and the CRO said it's planning more M&A for the year. News